Nyrada (ASX:NYR) announced the activation of its first clinical trial site for the PROTECT-MI Phase 2a study.
Nepean Hospital in New South Wales, Australia, has been selected as the lead facility to begin recruitment for this critical research phase.
The activation signifies a formal transition into clinical operations, following the completion of site governance, intensive staff training, and the logistical delivery of the trial medication.
Eligible patients presenting at Nepean Hospital following a myocardial infarction (heart attack) can now be screened and enrolled in the study.
The PROTECT-MI trial is designed to evaluate the safety and preliminary efficacy of Nyrada’s lead drug candidate, Xolatryp.
The treatment focuses on reducing myocardial injury—specifically damage caused by ischemia-reperfusion—which occurs when blood flow is restored to heart tissue after a blockage.
Despite being a primary driver of long-term heart failure and mortality, there are currently no approved therapies that directly target this specific type of injury.
Xolatryp works by inhibiting transient receptor potential canonical ion channels, a novel approach intended to mitigate the secondary damage that often follows a cardiac event.
At the time of reporting, Nyrada’s share price was $0.60.